Cyclana Bio

Cyclana Bio is an early-stage biotech targeting significant unmet needs in women's health, with an initial focus on endometriosis. The company's core innovation is a proprietary platform that analyzes menstrual fluid and the tissue extracellular matrix (ECM) to stratify disease, build human-relevant assays, and discover novel drug targets. Founded by alumni of Cambridge University and Altos Labs, the team combines expertise in biophysics, computational biology, and translational science to de-risk therapeutic discovery from the tissue level up. While currently in pre-clinical platform and target discovery, Cyclana aims to build a pipeline of first-in-class therapies for complex gynecological conditions.

Integrated platform utilizing menstrual fluid analysis and extracellular matrix (ECM)-centric 3D tissue modeling to stratify disease, build physiological assays, and discover novel therapeutic targets for gynecological conditions.

Competition includes other biotechs targeting endometriosis (e.g., ObsEva, AbbVie/Neurocrine's elagolix follow-ons, smaller startups) and large pharma with interest in women's health. Cyclana's differentiation lies in its unique focus on menstrual fluid and tissue-level ECM biology, a niche not widely pursued.